SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene …
2 days ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. Tech. Crypto. Biden Economy. Markets. Stocks: Most Actives. …
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene
2 days ago · Other Announcements by SRPT. The company’s president and CEO, Doug Ingram, is set to join Arrowhead’s board of directors. Alongside the above news, Sarepta also …
Sarepta Inks Global Licensing Deal With Arrowhead ... - Markets …
4 days ago · (RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Tuesday announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (ARWR) for …
Sarepta Therapeutics, Inc. (SRPT) Latest Stock News
Get the latest Sarepta Therapeutics, Inc. (SRPT) stock news and headlines to help you in your trading and investing decisions.
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote
Find the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other vital information to help you with your stock trading and investing.
SRPT Stock Price | Sarepta Therapeutics Inc. Stock Quote ... - MarketWatch
3 days ago · SRPT | Complete Sarepta Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Sarepta Therapeutics, Inc. (SRPT) Latest Stock News - Seeking Alpha
3 days ago · Join the community and access breaking stock news, subscribe to our leading investing newsletters and follow top analysts. Get the latest news and real-time alerts from …
Press Release - Sarepta Therapeutics, Inc.
Jun 22, 2023 · ELEVIDYS addresses the root genetic cause of Duchenne – mutations in the dystrophin gene that result in the lack of dystrophin protein – by delivering a gene that codes …
Sarepta Therapeutics (SRPT) Stock Surges on Gene Therapy …
Jun 20, 2024 · Under the expanded approval given Thursday, Sarepta can now market the drug for the vast majority of children with Duchenne muscular dystrophy, a lethal genetic disease.
Sarepta Therapeutics’ stock soars 38% after FDA expands use of its ...
Jun 21, 2024 · Sarepta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the …